您的位置: 首页 > 农业专利 > 详情页

3,4-Dihydropyrazine [2,3-b] pyrazin-2 (1H) -one compounds as mTOR kinase inhibitors for oncological indications and diseases associated with the mTOR / PI3K / Akt pathway
专利权人:
Signal Pharmaceuticals; LLC
发明人:
Elsner, Jan,Harris, Roy,Lee, Branden,Mortensen, Deborah,Packard, Garrick K.,Papa, Patrick,Perrin-Ninkovic, Sophie,Riggs, Jennifer,Sankar, Sabita,Sapienza, John,Shevlin, Graziella I.,Tehrani, Lida,Xu,
申请号:
ES14158171
公开号:
ES2562803T3
申请日:
2009.10.27
申请国别(地区):
ES
年份:
2016
代理人:
摘要:
A compound having the formula (II): ** Formula ** or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, wherein: R1 is pyridyl substituted with one or more substituents independently selected from the group consisting of C1- alkyl 8 substituted or unsubstituted, substituted or unsubstituted heterocyclyl, halogen, aminocarbonyl, cyano, hydroxyalkyl, -OR and -NR2, where each R is independently H, or a substituted or unsubstituted C1-4 alkyl; R2 is substituted or unsubstituted cycloalkyl, and R3 is H, or a substituted or unsubstituted C1-8 alkyl; wherein the term "substituted" denotes a substitution with any of the substituents recited in the subsequent claims or with halogen; I rent; hydroxyl; alkoxy; alkoxyalkyl; Not me; alkylamino; carboxy; nitro; cyano; thiol; thioether; imine; imide; amidine; guanidine; enamine; aminocarbonyl; acylamino; phosphonate; phosphine; thiocarbonyl; sulfonyl; sulfone; sulfonamide; ketone; aldehyde; ester; urea; urethane; oxime; hydroxyl amine; alkoxyamine; aralkoxyamine; N-oxide; hydrazine; hydrazide; hydrazone; azide; isocyanate; isothiocyanate; cyanate; thiocyanate; oxygen (>; = O); B (OH) 2, O (alkyl) aminocarbonyl; cocloalkyl, which may be monocyclic or polycyclic condensed or non-condensed; heterocyclyl; which can be monocyclic or polycyclic condensed or non-condensed; condensed or non-condensed monocyclic or polycyclic aryl or heteroaryl; aryloxy; aralkyloxy; heterocyclyloxy or heterocyclyl alkoxy.Un compuesto que presenta la fórmula (II): **Fórmula** o una sal, estereoisómero o tautómero farmacéuticamente aceptable del mismo, donde: R1 es piridilo sustituido con uno o más sustituyentes seleccionados de forma independiente del grupo que consiste en alquilo C1-8 sustituido o sin sustituir, heterociclilo sustituido o sin sustituir, halógeno, aminocarbonilo, ciano, hidroxialquilo, -OR y -NR2, donde cada R es de forma independiente H, o un alquilo C1-4 sustituido o sin sustituir; R2 es cicloalquilo sustituido o sin
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充